Spots Global Cancer Trial Database for Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
Official Title: A Multicenter, Randomized, Open-Label Study Comparing Three Alternative Dosing Regimens of Subcutaneous Azacitidine Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes
Study ID: NCT00102687
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine if azacitidine, combined with Best Supportive Care (BSC), is effective in treating myelodysplastic syndromes (MDS) when given according to a different doses and dosing schedules.
Detailed Description: Comparison/Control Interventions: The comparison is azacitidine at different doses and schedules. Duration of Intervention: Treatment lasted for a maximum of 18 cycles, which is up to 24 months.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Comprehensive Blood and Cancer Center, Research Department, Bakersfield, California, United States
Tower Cancer Research Foundation, Beverly Hills, California, United States
Cancer Center of Colorado Springs, The Oncology Clinic, PC, Colorado Springs, Colorado, United States
Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
Washington Cancer Institute, Washington, District of Columbia, United States
Florida Cancer Institute, New Port Richey, Florida, United States
Cancer Centers of Florida, P.A., Ocoee, Florida, United States
Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States
Oncology/Hematology Associates of Central Illinois, PC, Peoria, Illinois, United States
Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Hematology & Oncology Specialists LLC, Metairie, Louisiana, United States
Great Lakes Cancer Institute Breslin Cancer Center, Lansing, Michigan, United States
The Center for Cancer Care and Research, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Greater Dayton Cancer Center, Kettering, Ohio, United States
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
Oncology Services of Aberdeen, Aberdeen, South Dakota, United States
Avera Cancer Institute Leukemia-Bone Marrow Transplant Center, Sioux Falls, South Dakota, United States
McLeod Cancer and Blood Center, Johnson City, Tennessee, United States
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Texas Oncology, P.A., Bedford, Texas, United States
Texas Cancer Center at Medical City, Dallas, Texas, United States
Texas Oncology, PA, Fort Worth, Texas, United States
San Antonio Tumor & Blood Clinic, Fredericksburg, Texas, United States
Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States
Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk, Virginia, United States
Highline Medical Oncology, Burien, Washington, United States
Puget Sound Cancer Center, Edmonds, Washington, United States
Puget Sound Cancer Center, Seattle, Washington, United States
Cancer Care Northwest, Spokane, Washington, United States
Northwest Cancer Specialists, P.C., Vancouver, Washington, United States
Contact Details
Name: CL Beach
Affiliation: Celgene Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
